1. Lin OS, Kozarek RA, Cha JM. Impact of sigmoidoscopy and colonoscopy on colorectal cancer incidence and mortality: an evidence-based review of published prospective and retrospective studies. Intest Res. 2014; 12:268–274.
2. Lee HS, Jeon SW. Is retroflexion helpful in detecting adenomas in the right colon?: a single center interim analysis. Intest Res. 2015; 13:326–331.
3. Inra JA, Syngal S. Colorectal cancer in young adults. Dig Dis Sci. 2015; 60:722–733.
4. Kim YH, Noh R, Cho SY, Park SJ, Jeon SM, Shin HD, et al. Inhibitory effect of metformin therapy on the incidence of colorectal advanced adenomas in patients with diabetes. Intest Res. 2015; 13:145–152.
5. Kwon MJ, Kim YS, Bae SI, Park YI, Lee KJ, Min JH, et al. Risk factors for delayed post-polypectomy bleeding. Intest Res. 2015; 13:160–165.
6. Carroll MR, Seaman HE, Halloran SP. Tests and investigations for colorectal cancer screening. Clin Biochem. 2014; 47:921–939.
7. de Wijkerslooth TR, Stoop EM, Bossuyt PM, Meijer GA, van Ballegooijen M, van Roon AH, et al. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. Am J Gastroenterol. 2012; 107:1570–1578.
8. Chiang TH, Lee YC, Tu CH, Chiu HM, Wu MS. Performance of the immunochemical fecal occult blood test in predicting lesions in the lower gastrointestinal tract. CMAJ. 2011; 183:1474–1481.
9. Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med. 2007; 146:244–255.
10. van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology. 2008; 135:82–90.
11. Park DI, Ryu S, Kim YH, Lee SH, Lee CK, Eun CS, et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol. 2010; 105:2017–2025.
12. van Turenhout ST, Oort FA, Terhaar sive Droste JS, Coupé VM, van der Hulst RW, Loffeld RJ, et al. Hemorrhoids detected at colonoscopy: an infrequent cause of false-positive fecal immunochemical test results. Gastrointest Endosc. 2012; 76:136–143.
13. Stegeman I, de Wijkerslooth TR, Stoop EM, van Leerdam M, van Ballegooijen M, Kraaijenhagen RA, et al. Risk factors for false positive and for false negative test results in screening with fecal occult blood testing. Int J Cancer. 2013; 133:2408–2414.
14. Wen CP, David Cheng TY, Tsai SP, Chan HT, Hsu HL, Hsu CC, et al. Are Asians at greater mortality risks for being overweight than Caucasians? Redefining obesity for Asians. Public Health Nutr. 2009; 12:497–506.
15. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112:2735–2752.
16. Fraser CG, Allison JE, Halloran SP, Young GP. Expert Working Group on Fecal Immunochemical Tests for Hemoglobin. Colorectal Cancer Screening Committee. World Endoscopy Organization. A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J Natl Cancer Inst. 2012; 104:810–814.
17. Lai EJ, Calderwood AH, Doros G, Fix OK, Jacobson BC. The Boston bowel preparation scale: a valid and reliable instrument for colonoscopy-oriented research. Gastrointest Endosc. 2009; 69(3 Pt 2):620–625.
18. Sun Z, Migaly J. Review of hemorrhoid disease: presentation and management. Clin Colon Rectal Surg. 2016; 29:22–29.
19. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012; 143:844–857.
20. Rockey DC. Occult gastrointestinal bleeding. N Engl J Med. 1999; 341:38–46.
21. Saito H. Screening for colorectal cancer by immunochemical fecal occult blood testing. Jpn J Cancer Res. 1996; 87:1011–1024.
22. Rockey DC, Auslander A, Greenberg PD. Detection of upper gastrointestinal blood with fecal occult blood tests. Am J Gastroenterol. 1999; 94:344–350.
23. Denters MJ, Deutekom M, Essink-Bot ML, Bossuyt PM, Fockens P, Dekker E. FIT false-positives in colorectal cancer screening experience psychological distress up to 6 weeks after colonoscopy. Support Care Cancer. 2013; 21:2809–2815.
24. McCann J, Stockton D, Godward S. Impact of false-positive mammography on subsequent screening attendance and risk of cancer. Breast Cancer Res. 2002; 4:R11.
25. Nakama H, Kamijo N, Fujimori K, Horiuchi A, Abdul Fattah S, Zhang B. Immunochemical fecal occult blood test is not suitable for diagnosis of hemorrhoids. Am J Med. 1997; 102:551–554.
26. Johanson JF, Sonnenberg A. The prevalence of hemorrhoids and chronic constipation. An epidemiologic study. Gastroenterology. 1990; 98:380–386.
27. Haug U, Knudsen AB, Kuntz KM. How should individuals with a false-positive fecal occult blood test for colorectal cancer be managed? A decision analysis. Int J Cancer. 2012; 131:2094–2102.
28. Lee TJ, Hull MA, Rajasekhar PT, Clifford GM, Ritchie M, James P, et al. Aspirin users attending for NHS bowel cancer screening have less colorectal neoplasia: chemoprevention or false-positive faecal occult blood testing? Digestion. 2012; 85:278–281.